Compare Crispr Therapeutics AG (CRSP) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Royal Bank of Canada — how do they compare? Crispr Therapeutics AG trades at $50.76 (market cap $4.97B), while Royal Bank of Canada trades at $215.06 (market cap $294.58B). The key difference: Royal Bank of Canada is far larger — about 59.3× Crispr Therapeutics AG's market cap, and Royal Bank of Canada pays a 2.38% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | RY | |
|---|---|---|
Market Cap | $4.97B | $294.58B |
Sector | Health | Financials |
52-Week High | $76.78 | $214.04 |
52-Week Low | $44.34 | $128.46 |
Enterprise Value | $3.32B | — |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Royal Bank of Canada (RY) trades at $210.69, down 0.19% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a P/E of 19.45, net income margin of 31.85%, and ROE of 17.17%. Recent Q2 2026 earnings of $2.84 per share exceeded expectations, and the company announced a dividend increase to $1.76 per share alongside a share repurchase program.
RY's outlook is supported by robust profitability and shareholder returns, but risks include a high P/B ratio of 3.21 and macroeconomic sensitivity. Analyst sentiment is mixed with a slight hold bias, yet the stock's technical strength and dividend growth present a compelling case for income-focused investors amid cautious market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
